Jump Financial’s Clearside Biomedical CLSD Stock Holding History

Jump Financial’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,532	Closed	-$187K	–	1587
2021 Q4	$187K	Buy	4,532 +1,987	+78%	+$129K	0.01%	1130
2021 Q3	$229K	Buy	+2,545	New	+$225K	0.02%	805

Other funds holding CLSD

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jump Financial's CLSD Position: Q1 2022 in Review

Jump Financial sold out of Clearside Biomedical (CLSD) in Q1 2022, closing a stake of 4,532 shares — an estimated $187K sold.

Jump Financial first reported a position in CLSD in Q3 2021 and held it in 2 quarters. The position peaked at $229K in Q3 2021. 60 funds tracked by Wall St. Rank hold CLSD as of Q1 2022.

Jump Financial reported no remaining Clearside Biomedical position as of Q1 2022 after selling out during the quarter.
Jump Financial sold 4,532 Clearside Biomedical shares in Q1 2022, an estimated $187K.
Jump Financial first reported a position in Clearside Biomedical in Q3 2021 and held it in 2 quarters.
Jump Financial's Clearside Biomedical position peaked at $229K in Q3 2021.
60 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2022.

Based on Jump Financial's 13F filing for Q1 2022, filed 12 May 2022.